S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study

Fei Li; Feijiao Ge; Huayan Xu; Jianming Xu; Li Lin; Nong Xu; Ru Jia; Yan Wang; Yanqiao Zhang; Yi Ba; Yuxian Bai

首页> 外文期刊>The oncologist >S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study

【24h】

S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study

机译：吉西他滨难治性晚期胰腺癌单药治疗或联合白细胞素二线治疗的S-1：一项随机，开放标签，多中心，II期研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The oncologist》 |2014年第11期|共页
作者
Fei Li; Feijiao Ge; Huayan Xu; Jianming Xu; Li Lin; Nong Xu; Ru Jia; Yan Wang; Yanqiao Zhang; Yi Ba; Yuxian Bai;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, Multicenter, Phase II study [J] . GeF., XuN., BaiY., The oncologist . 2014,第11期

机译：S-1单药治疗或联合亚叶酸治疗二线治疗吉西他滨难治性晚期胰腺癌：一项随机，开放标签，多中心，II期研究
2. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer [J] . Ueno M., Okusaka T., Omuro Y., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第3期

机译：S-1加口服亚叶酸钙与S-1单药治疗吉西他滨难治性晚期胰腺癌的随机II期研究
3. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial) [J] . Ioka Tatsuya, Ueno Makoto, Ueno Hideki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：TAS-118（S-1加白光伏素）对吉西他滨 - 难治晚期胰腺癌患者的S-1：随机，开放标签，第3阶段研究（葡萄试验）
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized Open-Label Multicenter Phase II Study [O] . Feijiao Ge, Nong Xu, Yuxian Bai, 2014

机译：吉西他滨难治性晚期胰腺癌单药治疗或联合白细胞素二线治疗的S-1：一项随机开放标签多中心II期研究
7. S‐1 as Monotherapy or in Combination With Leucovorin as Second‐Line Treatment in Gemcitabine‐Refractory Advanced Pancreatic Cancer: A Randomized, Open‐Label, Multicenter, Phase II Study [O] . Feijiao Ge, Nong Xu, Yuxian Bai, 2014

机译：S-1作为单药治疗或与Leucovorin结合在吉西他滨 - 难治晚期胰腺癌中的二线治疗：随机，开放标签，多中心，II期研究

S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study

著录项

相似文献

相关主题

期刊订阅